Vertex Submits Applications in the U.S. and Europe for Approval of - TopicsExpress



          

Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. Vertex have submitted US and EU regulation applications for the approval of a potential new medicine for CF. This new drug would be a fully co-formulated combination of Lumacaftor and Ivacaftor. Exciting stuff! investors.vrtx/releasedetail.cfm?ReleaseID=880537
Posted on: Wed, 05 Nov 2014 12:19:23 +0000

Trending Topics



Recently Viewed Topics




© 2015